HomeAlprazolam C-Iv

Alprazolam C-Iv

Also known as: Alprazolam C-Iv

Benzodiazepine

Route: Oral

Check Alprazolam C-Iv Interactions →
28 interactions on record⛔ Black Box Warning

Alprazolam C-Iv has 28 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 17 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Alprazolam C-Iv should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
28
Contraindicated
4
Major
17
Moderate
7

Contraindicated (4)

  • Alprazolam C-Iv + ClarithromycinConcomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting
  • Alprazolam C-Iv + ItraconazoleConcomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting
  • Alprazolam C-Iv + KetoconazoleConcomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting
  • Alprazolam C-Iv + RitonavirStrong Inhibitors of CYP3A (except ritonavir) Clinical implication Concomitant use of alprazolam with strong CYP3A inhib

Major (17)

  • Alprazolam C-Iv + AlfentanilConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + BuprenorphineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + ButorpenolConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + CodeineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + DihydrocodeineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + FentanylConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + HydromorphoneConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + MeperidineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + MethadoneConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + MorphineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + OxycodoneConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + OxymorphoneConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + PentazocineConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + RemifentanilConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + SufentanilConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + TapentadolConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito
  • Alprazolam C-Iv + TramadolConcomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito

Moderate (7)

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.